Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei-Han Cheng

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 9, 2025
Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countriesWei-Han Cheng, Kinga Borsos, Zhixiao Wang, et al.
Advances in Therapy|June 7, 2023
Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World StudyAnthony Martinez, Wei-Han Cheng, Steven E Marx, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2026
Long-term efficacy of dupilumab versus tezepelumab in asthma: a matching-adjusted indirect comparisonKenneth R Chapman, Nick Freemantle, Patricia Guyot, et al.
Cancer Medicine|August 12, 2023
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community settingPankit Vachhani, Esprit Ma, Tao Xu, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2023
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community SettingAnda Gershon, Esprit Ma, Tao Xu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 23, 2023
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)Amer M Zeidan, Elizabeth S Mearns, Carmen D Ng, et al.
ERJ Open Research|August 5, 2025
Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGEGiorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, et al.
Advances in Therapy|October 27, 2021
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019Nancy Reau, Mark S Sulkowski, Emmanuel Thomas, et al.
Journal of Clinical Medicine|October 13, 2021
The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030Marleen van Dijk, Sylvia M Brakenhoff, Cas J Isfordink, et al.
American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 9, 2025
Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countriesWei-Han Cheng, Kinga Borsos, Zhixiao Wang, et al.
Advances in Therapy|June 7, 2023
Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World StudyAnthony Martinez, Wei-Han Cheng, Steven E Marx, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2026
Long-term efficacy of dupilumab versus tezepelumab in asthma: a matching-adjusted indirect comparisonKenneth R Chapman, Nick Freemantle, Patricia Guyot, et al.
Cancer Medicine|August 12, 2023
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community settingPankit Vachhani, Esprit Ma, Tao Xu, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2023
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community SettingAnda Gershon, Esprit Ma, Tao Xu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 23, 2023
Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)Amer M Zeidan, Elizabeth S Mearns, Carmen D Ng, et al.
ERJ Open Research|August 5, 2025
Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGEGiorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, et al.
Advances in Therapy|October 27, 2021
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019Nancy Reau, Mark S Sulkowski, Emmanuel Thomas, et al.
Journal of Clinical Medicine|October 13, 2021
The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030Marleen van Dijk, Sylvia M Brakenhoff, Cas J Isfordink, et al.
American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.
Pageof 3